|Acquired by||Bayer HealthCare|
|VENTURE FUNDING TOTAL||$33.2M|
|Series C, 10/07 |
Signet Healthcare Partners
|Venture Round, 2/10 |
|Series D, 4/10 |
DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaders such as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and NestlÃ©. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include WÃ¶lbern EquityPartner GmbH (Hamburg), NRW Bank (DÃ¼sseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KÃ¶lnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors.